---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-026853"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2025-07-23T23:59:59+00:00"
generated_at: "2026-05-18T03:14:15.961647+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Opus Genetics partners with Global RDH12 Alliance for OPGx-RDH12; $1.6M funding

## Summary
- Agreement with RDH12 Fund for Sight and Eyes on the Future provides up to $1.6M for OPGx-RDH12 development.
- Partnership includes risk-sharing structure and performance-based milestones; IND filing targeted by late 2025.
- If milestones missed, Funding Parties can exercise a non-exclusive license; Opus retains right to negotiate exclusive license back.
- During term, Opus cannot grant exclusive U.S. license to a third party without Funding Parties' consent.
- Term ends upon dosing three patients in Phase 1a/2b or first commercial sale, or if exclusive global licensee assumes obligations.

## SEC filing metadata
- accession: 0001140361-25-026853
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2025-07-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036125026853/0001140361-25-026853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036125026853/ef20052404_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-026853
- JSON: https://secwatch.observer/filing/0001140361-25-026853.json
- Plain text: https://secwatch.observer/filing/0001140361-25-026853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.